Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3452W HIGH $2.17
Volume
2.80 M
Value Traded
5.86 M
Short % Float
7.12%
0%Week
0%1 Month
+13.59%3 Month
+20.11%6 Month
-88.86%5 Year
-88.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
104.79 M
EPS (TTM)
-1.43
P/E Ratio
-
Ent. Value
-31.21 M
Total Shares
50.14 M
Float Shares
22.74 M
Insiders
54.64%
Institutions
34.42%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HLVX Catalyst Timeline
Dated clinical, regulatory and corporate events for HilleVax, Inc.
Past FDA Catalysts and PDUFA Decisions
How HLVX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every HLVX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HIL-214 | moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection | Phase 2b | 2024-07-08 | primary events: 51; vaccine arm events: 25; placebo arm events: 26; vaccine efficacy: 5%; confidence interval: -64%, 45%Read More | HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in InfantsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HERSHBERG ROBERTDirector, Officer (See Remarks) | Sell | -11,901 1,101,498 held | $1.76 | 02/11/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in HLVX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 0.8 % (14.3 %) | 21.13 M | 10.62 M |
HLVX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HLVX ranks across every disease it competes in
Competitive Position is a premium feature
See how HLVX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHLVX News
About HilleVax, Inc.
Founded2022
BIOPHARMAWATCH ELITE PLUS
Trade the next HLVX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime